绥美凯的推荐剂量是多少呢？

During the treatment of a disease, doctors often tell patients that they must take medications correctly. Only taking medications correctly can help patients on the road to disease treatment. If the patient does not take the medicine correctly, it is likely to cause secondary damage to the patient's disease. The same goes for taking cancer-targeted drugs, especially the AIDS-targeted drugs that are the first choice for many patients. Do you really know how to take them?

Suimeikai is a film-coated tablet, which appears white or off-white after removing the coating. It is composed of enteric-coated pellets. The general usage and dosage is to take this product under the guidance of a physician with experience in HIV infection. Dosage: Adults and Adolescents (Weighing at least 40kg) For adults and adolescents, the recommended dose of this product is one tablet, once daily. If the weight of adults or adolescents is less than 40kg, this product should not be given because this product is a fixed-dose tablet and the dose cannot be reduced. In addition to using it in compliance with the instructions, if there are special circumstances, it must be used under the guidance of a doctor.

If the patient misses a dose of this product and there are more than 4 hours before the next dose, the patient should take this product as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

kidney damage

Patients whose creatinine clearance is less than 50 mL/min are not recommended to take this product.

liver damage

Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment and therefore its use is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible.

children crowd

The safety and effectiveness of this product in children under 12 years of age have not been established. No data yet.

Adverse Reactions: There are limited clinical data, and the most commonly reported adverse reactions that are possibly or probably related to dolutegravir and abacavir/lamivudine (pooled data from 679 antiretroviral-naïve subjects who received this combination in Phase IIb to IIIb clinical trials) are nausea (12%), insomnia (7%), dizziness (6%), and headache (6%).